Table 4.
End-point dilution titers of IgG antibodies to SARS-CoV2 Spike and Nucleocapsid recombinant proteins in a subset of early and later phase samples.
| Sample ID | Age | Gender | Time since symptoms onset | IgG titer Spike | IgG titer Nucleocapsid |
|---|---|---|---|---|---|
| MP2594 | 60 | F | 5 | >12,800 | >12,800 |
| MP2575 | 55 | M | 7 | 200 | 400 |
| MP2636 | 75 | F | 8 | <100 | 800 |
| MP2684 | 75 | F | 8 | 3200 | 3200 |
| MP2702 | 74 | F | 10 | 800 | 6400 |
| MP2582 | NA | NA | 12 | <100 | 100 |
| MP2629 | NA | F | 30 | 800 | >12,800 |
| MP2708 | 74 | M | 31 | >12,800 | >12,800 |
| MP2683 | 71 | F | 32 | >12,800 | >12,800 |
| MP2705 | 73 | M | 33 | 3200 | 1600 |
| MP2694 | 75 | F | 46 | >12,800 | >12,800 |
| MP2628 | 68 | M | 47 | 6400 | >12,800 |